IMUGENE LIMITED — Board/Management Information 2018

Aug 22, 2018

ASX Announcement

==> picture [168 x 74] intentionally omitted <==

Imugene appoints Dr Mark Marino Chief Medical Officer

• Clinical development specialist with training in Internal Medicine and a FDA fellowship in Clinical Pharmacology with 20 years drug development experience

• Advanced a broad range of therapeutics in oncology and other important indications

Sydney, Australia - 23 August 2018 – Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announced the appointment of Dr Mark T. Marino as Chief Medical Officer (CMO).

Dr Marino will lead the Company’s global clinical development, regulatory and medical monitoring activities.

Dr Marino brings deep experience to the Company, having held senior level clinical development/leadership & CMO positions at top tier pharmaceutical companies, including Daiichi-Sankyo, Hoffman-La Roche AG, and Novartis Pharmaceuticals Corp.

In his previous roles, Dr Marino headed teams in oncology, cardiology, endocrinology and rare-diseases where he was responsible for clinical development through to commercialization and life cycle management.

He also successfully engaged key stakeholders including the scientific community, scientific boards, advocacy groups and key opinion leaders.

Prior to his move into the pharmaceutical industry, Dr Marino spent 7 years with the US Military’s Walter Reed Army Institute of Research, the Walter Reed Army Medical Center and the Uniformed Services University of the Health Sciences.

Dr Marino holds a Medical Doctor degree from the Albert Einstein College of Medicine and a Bachelor of Science in Chemistry from the United States Military Academy.

Welcoming Dr Marino, Imugene Managing Director and CEO Leslie Chong said: “We look forward to the valuable contribution Dr. Marino will make to advance our important immuno-oncology programs and are very pleased someone with his track record and experience is joining Imugene as Chief Medical Officer.

IMUGENE LIMITED ACN 009 179 551 Phone +61 3 9824 5254 Fax +61 3 9822 7735 Website www.imugene.com

"Based in the USA, Dr Marino will support our global clinical development activities as well as our interactions with regulatory agencies and other key stakeholders.

His commercial drug development experience, including his contribution in obtaining regulatory approval of a number of innovative new therapies will be very important in supporting Imugene in the rapid development of its expanded pipeline of immuneoncology therapeutics aimed at addressing areas of high unmet need.”

Dr Marino said, “Imugene has an exciting clinical portfolio of promising immuneoncology candidates. I am excited to be joining the Company at this pivotal stage in its development and look forward to working with the team to help bring new medicines to market, which have the potential to meaningfully improve millions of patients’ lives.”

For further information please contact:

Leslie Chong Managing Director and Chief Executive Officer T: 0458 040 433 Follow us on Twitter @ TeamImugene

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technology seeks to harness the body’s immune system to generate antibodies against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody therapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies will become a foundation treatment for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

IMUGENE LIMITED ACN 009 179 551 Phone +61 3 9824 5254 Fax +61 3 9822 7735 Website www.imugene.com

2